Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab in Systemic Sclerosis
NCT07842523Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in systemic sclerosis (SSc), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
obinutuzumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07842523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07842523.